Answer
The drug's price hike occurred in 2015 when Martin Shkreli, Then-CEO of Turing Pharmaceuticals, acquired the rights to Daraprim, a decades-old drug used to treat toxoplasmosis. Shkreli raised the price of a single tablet from $13.50 to $750, an increase of over 5,000%, sparking widespread public outrage and scrutiny of the pharmaceutical industry's pricing practices.